Continuous intravenous octreotide treatment for acute experimental pancreatitis

被引:10
作者
Greenberg, R
Haddad, R
Kashtan, H
Brazowski, E
Graff, E
Skornick, Y
Kaplan, O
机构
[1] Tel Aviv Med Ctr, Dept Surg A, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel
[3] Tel Aviv Med Ctr, Biochem Lab, IL-64239 Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
关键词
octreotide; intravenous treatment; experimental pancreatitis;
D O I
10.1159/000007637
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The efficacy of octreotide, the synthetic analogue of the hormone somatostatin, for the treatment of acute pancreatitis is controversial. Octreotide has been commonly administered in subcutaneous bolus injections; however, continuous intravenous infusion may be advantageous for acute conditions. Methods: Acute experimental pancreatitis was induced in rats by intraparenchymal injections of 1 mi 10% sodium taurocholate, and octreotide (1 mu g/kg/h, dissolved in physiological solution, intravenously was started 4 h later and continuously infused for 48 h. Physiological solution infusions, in identical volumes, were used in the controls. The following parameters were examined: mortality; macroscopic and histological damage; hematocrit; plasma pH; acid-base balance; serum glucose; calcium, and amylase. Results: Octreotide treatment had a striking effect on mortality: 8.3 versus 91.6% in the treatment and control groups, respectively (p < 0.001), Octreotide also ameliorated pancreatic edema and intestinal dilatation, and had significant beneficial effects on histopathological damage and the biochemical alterations which are associated with acute pancreatitis. Conclusions: Continuous intravenous octreotide infusion is a potentially efficacious therapeutic method for acute pancreatitis.
引用
收藏
页码:125 / 131
页数:7
相关论文
共 44 条
[1]   EXPERIMENTAL PANCREATITIS IN THE RAT - DEVELOPMENT OF PANCREATIC NECROSIS, ISCHEMIA AND EDEMA AFTER INTRADUCTAL SODIUM TAUROCHOLATE INJECTION [J].
AHO, HJ ;
NEVALAINEN, TJ ;
AHO, AJ .
EUROPEAN SURGICAL RESEARCH, 1983, 15 (01) :28-36
[2]  
AUGELLI NV, 1989, AM SURGEON, V55, P389
[3]   Octreotide ameliorates glucose intolerance following acute experimental pancreatitis [J].
Avni, B ;
Haddad, R ;
Kashtan, H ;
Kaplan, D ;
Graf, E ;
Siegal, A ;
Skornick, Y ;
Kaplan, O .
DIGESTIVE DISEASES AND SCIENCES, 1998, 43 (01) :193-202
[4]   OCTREOTIDE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN CONDITIONS ASSOCIATED WITH EXCESSIVE PEPTIDE SECRETION [J].
BATTERSHILL, PE ;
CLISSOLD, SP .
DRUGS, 1989, 38 (05) :658-702
[5]  
BAWNIK JB, 1974, DIG DIS, V19, P1143
[6]   EFFECTS OF SOMATOSTATIN AND A LONG-ACTING SOMATOSTATIN ANALOG ON THE PREVENTION AND TREATMENT OF EXPERIMENTALLY INDUCED ACUTE-PANCREATITIS IN THE RAT [J].
BAXTER, JN ;
JENKINS, SA ;
DAY, DW ;
ROBERTS, NB ;
COWELL, DC ;
MACKIE, CR ;
SHIELDS, R .
BRITISH JOURNAL OF SURGERY, 1985, 72 (05) :382-385
[7]   CONTROLLED TRIAL OF HIGH-DOSE OCTREOTIDE IN TREATMENT OF ACUTE-PANCREATITIS - EVIDENCE OF IMPROVEMENT IN DISEASE SEVERITY [J].
BEECHEYNEWMAN, N .
DIGESTIVE DISEASES AND SCIENCES, 1993, 38 (04) :644-647
[8]   OCTREOTIDE IN THE TREATMENT OF ACUTE-PANCREATITIS - RESULTS OF A UNICENTER PROSPECTIVE TRIAL WITH 3 DIFFERENT OCTREOTIDE DOSAGES [J].
BINDER, M ;
UHL, W ;
FRIESS, H ;
MALFERTHEINER, P ;
BUCHLER, MW .
DIGESTION, 1994, 55 :20-23
[9]   POTENTIAL ROLE OF SOMATOSTATIN AND OCTREOTIDE IN THE MANAGEMENT OF ACUTE-PANCREATITIS [J].
BUCHLER, MW ;
BINDER, M ;
FRIESS, H ;
MALFERTHEINER, P .
DIGESTION, 1994, 55 :16-19
[10]  
CARBALLO F, 1991, Digestion, V49, P12